News About: R&D
RDA, Kwangdong sign on new drug developmentKwangdong Pharm will join the Rural Development Administration (RDA) in a development project to create new antitumor agent using corn silk (Zea mays).
The RDA signed a memor...
|
Nexavar improves survival in liver cancer
Nexavar (sorafenib) tablets significantly improved overall survival by 47.3 percent in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), according to Bayer HealthCare.
In a local sym...
Daewha Pharm wins Korean patent for amodipine
Daewha Pharm announced in its regulatory filing on June 11 that it acquired a Korea patent for manufacturing film-coated granules containing amodipine or S-amlodipine salts and excipients.
S-amlodipine salts are sa...
Ilyang to enter Phase I/II studies for new investigational leukemia drugIlyang Pharm says it will conduct Phase I and II trials simultaneously for its new leukemia medicine “IY5511” in 10 hospitals at home and abroad for 18 months, after getting the...
|
Daewon, Samyang to strengthen co-development of new drugs
Daewon Pharm signed a memorandum of understanding with Samyang Corporation to jointly develop three new tranquilizers using Samyang’s fast dissolving tablet (FDT; also called “orally dsintegrating tablet”) technology....
Akreos MI60 to be available in KoreaBausch & Lomb Korea, the Korean unit of Bausch & Lomb, says it has received a marketing approval of its Akreos AO Micro Incision Intraocular Lens (Akreos MI60).
In keeping wi...
|
KFDA approves new indication of Crestor, “therosclerosis”
AstraZeneca Korea says that the Korea Food and Drug Administration has approved Crestor (rosuvastatin calcium) as an adjunct to diet to slow the progression of atherosclerosis in patients with elevated cholesterol.
...
Estimated human effective dose essential for success of new drug development
For successful development of a new drug domestic drug makers should determine its effective dose based on animal experiment, said a Korean scientist of the U.S. Bristol-Myers Squibb Co.
In an international symposi...
Kwangdong faces damage suit
Mypharm said on May 21 it would seek 10.0 billion won in compensation from Kwangdong Pharm for sales losses caused by the Kwangdong’s illegal use of a trademark “Humassen” owned by Mypharm.
Humassen is a human pla...
Patent protection and patient access should be balanced
The excessive patent protection should be avoided as it may discourage the development of any innovative medicines as well as patient access, according to Park Sylvia a chief researcher at the Korea Institute for Heal...
